Frontlight ResearchEarly access
CompletedNo phase
Juvenile Idiopathic Arthritis (JIA) Registry
Key facts
- Who runs it
- AbbVie
- Where
- Akron, Bismarck, Boston, Burlington, Chicago, Cincinnati, Columbus, Delray Beach, Durham, Ellicott City, Indianapolis, Kingsport, Little Rock, Los Angeles, Louisville, Memphis, Milwaukee, New Hyde Park, Omaha, Peoria, Philadelphia, Phoenix, Portland, Rochester, Round Rock, Salt Lake City, Seattle, Tucson, Valhalla, Washington D.C., and West Orange, United StatesSee the 32 sitesAlso in 16 other countries, 60 sites
- Trial code
- Status
- Completed
- People taking part
- 849 people enrolled
- Started
- 11 Jul 2008
- Ended
- 1 Feb 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- adalimumab
- Methotrexate
- Record updated
- 4 February 2025
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- For a patient enrolling into the HUMIRA® arm; a pediatric patient diagnosed at any time with moderately to severely active polyarticular or polyarticular-course JIA (defined as arthritis affecting >= 5 joints at the time of diagnosis of polyarticular or polyarticular-course JIA) who has been prescribed HUMIRA® therapy according to the local approved HUMIRA® product labeling and meets one of the following criteria:
- Enrolled patients are 4 to 17 years of age as per approved HUMIRA® product label with the addition of JIA patients 2 to < 4 years of age in countries with available local approval for this group of patients at the time of consent to the registry
- Newly initiated (within 24 months of registry entry) on HUMIRA® therapy and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy, and the physician can provide available source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy
- Or is entering after participation (within 24 months of registry entry or, if longer, continuously treated at the same site) in an AbbVie Humira sponsored study, regardless of age or the number of joints with symptoms of JIA, and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide available source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy
- For a patient enrolling into the MTX arm; a pediatric patient diagnosed at any time with moderately to severely active polyarticular or polyarticular-course JIA (defined as arthritis affecting >= 5 joints at the time of diagnosis of polyarticular or polyarticular-course JIA) who is prescribed MTX therapy alone or in combination with other disease modifying anti-rheumatic drugs (DMARDs) according to the local product labeling (initiated treatment within 24 months of registry entry) and has received continuous therapy and the physician can available provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy
- Patients who were treated in the MTX arm of this registry and prematurely discontinued from the MTX arm due to being a non-responder, or became intolerant of MTX treatment or are in need of combination treatment with HUMIRA® therapy may be eligible to enroll into the HUMIRA® treatment arm if all ongoing AEs/SAEs have been resolved, and they meet inclusion criteria and can enroll within the registry enrollment period. In case of ongoing AEs/SAEs at the time of the treatment arm switch, the AbbVie Designated Physician should be contacted to assess the eligibility of patient to roll into Humira treatment arm
- Parent or guardian has voluntarily signed and dated an informed consent/patient authorization form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) if applicable according to local law, after the nature of the registry has been explained and the patient's parent or legal guardian has had the opportunity to ask questions. Pediatric patients will be included in all discussions as per applicable local regulations in order to obtain verbal or written assent
Who cannot take part
- Patients should not be enrolled into the HUMIRA® or MTX arm if they require on-going treatment with Kineret® (anakinra), Orencia® (abatacept), Rituxan® (rituximab), Enbrel® (etanercept), and Remicade® (infliximab), or any other approved biologic agents or investigational agents
- Patients should not be enrolled into the MTX arm if they have had prior treatment with any investigational agent or anti-rheumatic biologic therapy such as, but not limited to, Orencia® (abatacept), Enbrel® (etanercept), Remicade® (infliximab), Rituxan® (rituximab), or Actemra® (tocilizumab)
- Patients should not be enrolled into the HUMIRA® or Methotrexate (MTX) arm if they cannot be prescribed and treated in accordance with the approved local HUMIRA® and/or with the local MTX product label
Where in United States
Also in 16 other countries, 60 sites
- Akron Children's HospitalAkron, United States
- Bone Spine Sports/Medctr OneBismarck, United States
- Tufts Medical CenterBoston, United States
- Children's Speciality CenterBurlington, United States
- Ann & Robert H Lurie Children's Hospital of ChicagoChicago, United States
- The University of Chicago Medical CenterChicago, United States
- University of CincinnatiCincinnati, United States
- Nationwide Children's HospitalColumbus, United States
- Arthritis Associates South FLDelray Beach, United States
- Duke Cancer CenterDurham, United States
- Arthritis Care Spec. of MDEllicott City, United States
- Indiana UniversityIndianapolis, United States
- Arthritis Associates of KingsportKingsport, United States
- Arkansas Children's HospitalLittle Rock, United States
- Children's Hospital Los AngelesLos Angeles, United States
- University of LouisvilleLouisville, United States
- Dr. Ramesh GuptaMemphis, United States
- Children's Hospital Wisconsin - Milwaukee CampusMilwaukee, United States
- North Shore University HospitalNew Hyde Park, United States
- Creighton Univ Med CtrOmaha, United States
- Methodist Medical Group RheumPeoria, United States
- St. Christopher's HospitalPhiladelphia, United States
- AZ Arthritis and Rheumotology Research, PLLCPhoenix, United States
- Legacy Emanuel Medical CenterPortland, United States
- University of Rochester Medical CenterRochester, United States
- Scott & White Health CareRound Rock, United States
- University of UtahSalt Lake City, United States
- Seattle Children's HospitalSeattle, United States
- Catalina Pointe Clinical ResearchTucson, United States
- New York Medical CollegeValhalla, United States
- Children's National Medical CenterWashington D.C., United States
- St. Barnabas Ambulatory CareWest Orange, United States
About the trial
What the trial wants to find out
This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.
The 2 groups in the trial
- HUMIRA® Treatment Arm
For patients taking HUMIRA®
Treatment: adalimumab
- Methotrexate Treatment Arm
For patients taking Methotrexate
Treatment: Methotrexate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE
- Record updated
- 4 February 2025